3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Conditions
Lymphoma, Non-Hodgkin
3
Recurrence
2
Myasthenia Gravis
2
Neoplasms, Plasma Cell
1
Neoplasms
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Hematologic Neoplasms
1
Interventions
rozanolixizumab
10
zilucoplan
8
efgartigimod alfa
8
Rituximab
7
Cyclophosphamide
7
telitacicept
6
fludarabine
6
eculizumab
5
Prednisone
5
ravulizumab
4
Pyridostigmine Bromide
4
Immunoglobulins, Intravenous
4
Hizentra
4
Tacrolimus
3
Mycophenolic Acid
3
HBM9161
3
Amifampridine
3
thymoglobulin
2
inebilizumab
2
Prednisolone
2
Exercise
2
tofacitinib
1
tocilizumab
1
talquetamab
1
satralizumab
1
sargramostim
1
rhoA GTP-Binding Protein
1
remibrutinib
1
prednylidene
1
iscalimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Myasthenia Gravis
×
inebilizumab
×
Clear all
NCT06987539
2026-05-29
THYME
Amgen
Phase 2
Recruiting
15 enrolled
NCT04524273
2026-05-15
MINT
Amgen
Phase 3
Active not recruiting
238 enrolled
36 charts